AstraZeneca Operating Income from 2010 to 2026
| ZEGA Stock | EUR 75.50 0.00 0.00% |
Operating Income | First Reported 2017-03-31 | Previous Quarter 3.6 B | Current Value 3 B | Quarterly Volatility 1.1 B |
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Interest Expense of 1.1 B, Selling General Administrative of 15.7 B or Total Revenue of 37.6 B, as well as many indicators such as . AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
AstraZeneca | Operating Income |
The Operating Income trend for AstraZeneca PLC offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether AstraZeneca PLC is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest AstraZeneca PLC's Operating Income Growth Pattern
Below is the plot of the Operating Income of AstraZeneca PLC over the last few years. Operating Income is the amount of profit realized from AstraZeneca PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of AstraZeneca PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. AstraZeneca PLC's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AstraZeneca PLC's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
AstraZeneca Operating Income Regression Statistics
| Arithmetic Mean | 5,355,008,824 | |
| Geometric Mean | 4,202,699,912 | |
| Coefficient Of Variation | 74.65 | |
| Mean Deviation | 2,997,425,260 | |
| Median | 4,203,000,000 | |
| Standard Deviation | 3,997,682,192 | |
| Sample Variance | 15981462.9T | |
| Range | 13.4B | |
| R-Value | 0.61 | |
| Mean Square Error | 10656970.9T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | 484,689,216 | |
| Total Sum of Squares | 255703406.5T |
AstraZeneca Operating Income History
About AstraZeneca PLC Financial Statements
AstraZeneca PLC stakeholders use historical fundamental indicators, such as AstraZeneca PLC's Operating Income, to determine how well the company is positioned to perform in the future. Although AstraZeneca PLC investors may analyze each financial statement separately, they are all interrelated. For example, changes in AstraZeneca PLC's assets and liabilities are reflected in the revenues and expenses on AstraZeneca PLC's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AstraZeneca PLC. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | 13.7 B | 14.4 B |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.